Nalbuphine hydrochloride

Drugs that may interact with nalbuphine hydrochloride include barbiturate anesthetics, cimetidine, CNS depressants. 

Morphinan derivatives butorphanol tartrate nalbuphine hydrochloride... 

Nalbuphine hydrochloride is structurally related to oxymorphone and naloxone. It is approximately equipotent with morphine. Nalbuphine is metabolised in the liver to inactive metabolites. The plasma terminal half-life is approximately 5 h. The onset of analgesia is within 2-3 min of intravenous administration and 15 min after intramuscular injection, and lasts 3-6 h with an adult dose of 10 mg. With equi-analgesic doses, similar degrees of respiratory depression to that of morphine occur up to a dose of approximately 0.45 mg-kg-1. With higher doses a ceiling effect occurs. Sedation, possibly mediated by K-receptor activation, occasionally occurs. The incidence of psychotomimetic side effects is lower than with pentazocine. The abuse potential is low, but is can cause withdrawal symptoms in opioid-dependent subjects. It has occasionally been used to reverse opioid-induced respiratory depression. 

Pugh, G.C., Brown, D.T., Drummond, G.B. Effect of nalbuphine hydrochloride on the ventilatory and occlusion pressure responses to carbon dioxide in volunteers, Br. J. Anaesth. 1989, 62, 601-609. 

Dose. 10 to 20 mg of nalbuphine hydrochloride parenterally, every 3 to 6 hours. 

Nalbuphine hydrochloride (nubain) is used to produce analgesia. Because it is an agonist-antagonist, administration to patients who have been receiving morphine-like opioids may create difficulties unless a brief drug-free interval is interposed. The usual adult dose is 10 mg parenterally every 3 to 6 hours this may be increased to 20 mg in nontolerant individuals. 

H31NO2, Lycoctonine alkaloid derivative, 42B, 460 1H31NO5, Oxotuberostemonine, 38B, 583 1H32CINO6, Nalbuphine hydrochloride dihydrate,... 

---